Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

49.00 -0.51 (-1.03%)
Delayed Quote Updated: 11:42 AM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
45 46 Next >
News headline image
This Is What Whales Are Betting On GSK ↗
 
Via Benzinga
News headline image
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information ↗
 
Via Benzinga
News headline image
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories ↗
Reuters 
Via Benzinga
News headline image
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' ↗
 
Via Benzinga
News headline image
3 Pharma Stocks That Could Benefit from Global Healthcare Trends ↗
The best pharma stocks to buy are those that are poised to be greatly boosted by drugs that are well-positioned to become blockbusters. 
Via InvestorPlace
News headline image
Daily Stock Analysis: GSK ↗
By my dogcatcher ideal, this is a proper time to buy GSK shares, based on their dividends for 2023. 
Via Talk Markets
News headline image
How Is The Market Feeling About GSK? ↗
 
Via Benzinga
News headline image
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna? ↗
An approved RSV vaccine could be the next big thing for these companies. 
Via The Motley Fool
News headline image
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales ↗
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D... 
Via Benzinga
News headline image
GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
From GSK plc
Via Business Wire
News headline image
3 High Dividend Stocks With Attractive Total Return Potential ↗
In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns. 
Via InvestorPlace
News headline image
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race ↗
These companies aren't working on a vaccine, but a monoclonal antibody. 
Via Investor's Business Daily
News headline image
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock? ↗
This vaccine candidate could help tackle the respiratory syncytial virus. 
Via The Motley Fool
News headline image
March 2023 Stock Considerations ↗
The calendar has turned, and a new trading month is upon us. 2023 is flying by as two months are already in the books, and that fact simply highlights the importance of staying invested in the stock... 
Via Talk Markets
News headline image
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK's Candidate Soon After Pfizer's ↗
 
Via Benzinga
News headline image
3 Crucial Things to Know About Moderna Right Now ↗
This vaccine leader is preparing for a post-pandemic world. 
Via The Motley Fool
News headline image
GSK's Relief For Few Months, First Trial Claiming Zantac Caused Cancer Pushed Into Late 2023 ↗
The first scheduled trial expected next week, related to GSK Plc's (NYSE: GSK) Zantac associated with cancer, has been postponed, likely by several months. 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields ↗
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
News headline image
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows ↗
 
Via Benzinga
News headline image
Intel and 9 Other Companies With Dividend Cuts in 2023 ↗
Intel announced that it would cut its dividend by a whopping 66%. Here are nine other companies that have also seen dividend cuts this year. 
Via InvestorPlace
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
My 3 Biggest Stock Market Predictions for March ↗
These three trends will likely drive revenue and share prices. 
Via The Motley Fool
News headline image
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue ↗
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among... 
Via Benzinga
News headline image
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals ↗
 
Via Benzinga
News headline image
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out ↗
Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.  
Via Benzinga
News headline image
Dividend Income Update For January 2023 ↗
Without rehashing the wild ride we experienced in the market over the last few months, I could find comfort in one thing: my dividends (even if dividend cuts are on the table these days). Let's see how... 
Via Talk Markets
News headline image
Week In Review: CANbridge In-Licenses Gene Therapy For Rare Disease From UMass ↗
CANbridge Pharma exercised an option for global rights to a novel second-gen gene therapy from UMass Chan medical school. Additionally, Zhimeng Biopharma signed an agreement to out-license global... 
Via Talk Markets
News headline image
FDA AdComm Votes In Favor Of GSK's Jemperli Single Arm Trial Plan For Rectal Cancer Setting ↗
 
Via Benzinga
News headline image
FDA Grants Complete Approval For GSK's Jemperli For Endometrial Cancer ↗
 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.